Total: $73.29M

Company

Location

Amt. (M)

Details

Date


Calypso Biotech

Geneva

€2.5 ($3.24)

Calypso, a Merck Serono spinoff, received $3.24M in seed funding

3/5/13

Carolus Therapeutics Inc.

San Diego

$2.25

Carolus received $2.25M in a debt facility from Square 1 Bank

3/6/13

Dezima Pharma BV

Naarden, the Netherlands

€14.2 ($18.6)

Dezima raised $18.6M, including €9.8M in a Series A round, and a €4.4M loan from Dutch Ministry of Economic Affairs agency Agentschap NL

3/1/13

InteRNA Technologies BV

Bilthoven, the Netherlands

ND

InteRNA closed an equity financing round, with participation from new investors Innovation and Investment Fund Gelderland and several angel investors

3/27/13

Kala Pharmaceuticals Inc.

Waltham, Mass.

$11.5

Kala raised $11.5M in a Series A round through Crown Venture Fund LLC, joined by Lux Capital Management, Polaris Venture Partners and Third Rock Ventures

3/1/13

Progenitor Labs Ltd.

London

£4 ($5.8)

Progenitor raised $5.8M in seed financing from SR One's UK Fund

3/12/13

Savara Pharmaceuticals Inc.

Austin, Texas

$7.4

Savara closed a $7.4M second tranche of a Series B financing, bringing the total raised to $16M

3/21/13

TauRx Pharmaceuticals Ltd.

Singapore

$10.5

TauRx received an equity investment of $10.5M from Dundee Corp., of Toronto

3/6/13

Theraclone Sciences Inc.

Seattle

$14

Theraclone raised $14M in a financing with existing investors ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo, which committed $8M; an additional $6M came from a credit facility with MidCap Financial and Silicon Valley Bank

3/27/13


Notes:

Currency conversions are based on exchange rates at the time of the deal.

** Denotes the date the item ran in BioWorld International.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ND = Not disclosed.